These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32595128)

  • 1. Angiotensin II for the treatment of septic shock in a neutropenic patient with T-cell acute lymphoblastic leukaemia.
    Bui AD; Helgeson SA; Guru PK; Sanghavi DK
    BMJ Case Rep; 2020 Jun; 13(6):. PubMed ID: 32595128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin II in septic shock.
    Jadhav AP; Sadaka FG
    Am J Emerg Med; 2019 Jun; 37(6):1169-1174. PubMed ID: 30935784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II in Decompensated Cirrhosis Complicated by Septic Shock.
    Coleman PJ; Nissen AP; Kim DE; Ainsworth CR; McCurdy MT; Mazzeffi MA; Chow JH
    Semin Cardiothorac Vasc Anesth; 2020 Sep; 24(3):266-272. PubMed ID: 31540560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA Approval of Angiotensin II for the Treatment of Hypotension in Adults with Distributive Shock.
    Senatore F; Jagadeesh G; Rose M; Pillai VC; Hariharan S; Liu Q; McDowell TY; Sapru MK; Southworth MR; Stockbridge N
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):11-20. PubMed ID: 30144016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin for septic shock unresponsive to noradrenaline.
    Yunge M; Petros A
    Arch Dis Child; 2000 May; 82(5):388-9. PubMed ID: 10799431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. THE ROLE OF ANGIOTENSIN -2 IN THE PATHOGENESIS OF SEPTIC SHOCK DURING MULTIORGAN DYSFUNCTION SYNDROME (REVIEW).
    Rurua M; Machavariani K; Sanikidze T; Shoshiashvili V; Pachkoria E; Ratiani L
    Georgian Med News; 2022 Feb; (323):157-161. PubMed ID: 35271489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study.
    Chawla LS; Busse L; Brasha-Mitchell E; Davison D; Honiq J; Alotaibi Z; Seneff MG
    Crit Care; 2014 Oct; 18(5):534. PubMed ID: 25286986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II in Refractory Septic Shock.
    Antonucci E; Gleeson PJ; Annoni F; Agosta S; Orlando S; Taccone FS; Velissaris D; Scolletta S
    Shock; 2017 May; 47(5):560-566. PubMed ID: 27879559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II: a new approach for refractory shock management?
    Kimmoun A; Levy B
    Crit Care; 2014 Dec; 18(6):694. PubMed ID: 25645552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II and Vasopressin for Vasodilatory Shock: A Critical Appraisal of Catecholamine-Sparing Strategies.
    Heavner MS; McCurdy MT; Mazzeffi MA; Galvagno SM; Tanaka KA; Chow JH
    J Intensive Care Med; 2021 Jun; 36(6):635-645. PubMed ID: 32223515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasodilatory shock in the ICU and the role of angiotensin II.
    Wakefield BJ; Sacha GL; Khanna AK
    Curr Opin Crit Care; 2018 Aug; 24(4):277-285. PubMed ID: 29877879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Renin-Angiotensin-Aldosterone System Dysfunction With Angiotensin II in High-Renin Septic Shock.
    Chow JH; Wallis M; Lankford AS; Chancer Z; Barth RN; Scalea JR; LaMattina JC; Mazzeffi MA; McCurdy MT
    Semin Cardiothorac Vasc Anesth; 2021 Mar; 25(1):67-73. PubMed ID: 32787515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulation of the renin-angiotensin system in septic shock: Mechanistic insights and application of angiotensin II in clinical management.
    Senatore F; Balakumar P; Jagadeesh G
    Pharmacol Res; 2021 Dec; 174():105916. PubMed ID: 34597810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II in Vasodilatory Shock.
    Wakefield BJ; Busse LW; Khanna AK
    Crit Care Clin; 2019 Apr; 35(2):229-245. PubMed ID: 30784606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications.
    Mesters RM; Helterbrand J; Utterback BG; Yan B; Chao YB; Fernandez JA; Griffin JH; Hartman DL
    Crit Care Med; 2000 Jul; 28(7):2209-16. PubMed ID: 10921542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hypotension in septic shock.
    Pastor CM; Morel DR
    Lancet; 1996 Mar; 347(9001):622; author reply 622-3. PubMed ID: 8596355
    [No Abstract]   [Full Text] [Related]  

  • 17. The ATHOS-3 trial, angiotensin II and The Three Musketeers.
    Bellomo R; Hilton A
    Crit Care Resusc; 2017 Mar; 19(1):3-4. PubMed ID: 28215124
    [No Abstract]   [Full Text] [Related]  

  • 18. Regional differences in the treatment of refractory vasodilatory shock using Angiotensin II in High Output Shock (ATHOS-3) data.
    Abril MK; Khanna AK; Kroll S; McNamara C; Handisides D; Busse LW
    J Crit Care; 2019 Apr; 50():188-194. PubMed ID: 30553989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of hypotension in septic shock.
    Whiteley SM; Dade JP
    Lancet; 1996 Mar; 347(9001):622. PubMed ID: 8596354
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiotensin II in septic shock.
    Corrêa TD; Takala J; Jakob SM
    Crit Care; 2015 Mar; 19(1):98. PubMed ID: 25886853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.